Literature DB >> 15355567

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.

Rachel Nyambo1, Neil Cross, Jenny Lippitt, Ingunn Holen, Gorden Bryden, Freddie C Hamdy, Colby L Eaton.   

Abstract

UNLABELLED: Tumor-derived OPG has recently been shown to protect prostate cancer cells from apoptosis. This study has confirmed that bone marrow stromal cell-derived OPG also suppresses cytokine-induced apoptosis in this tumor type, suggesting that it may be the presence of bone-derived OPG that is responsible for the observed preference of these cells in colonizing the skeleton.
INTRODUCTION: Metastasis to the skeleton occurs in around 70% of patients with advanced prostate cancer (CaP), suggesting that the bone microenvironment may provide factors that favor the growth and survival of prostate cancer cells. Osteoprotegerin (OPG) is a molecule involved in bone remodeling, where it acts as an inhibitor of osteoclastogenesis, but it is also a decoy receptor for TRAIL/Apo 2L, a member of the TNF family of pro-apoptotic cytokines. The aim of this study was to determine whether OPG produced by human bone marrow stromal cells could protect prostate cancer cells from TRAIL-induced apoptosis.
MATERIALS AND METHODS: Human bone marrow stromal cell cultures were generated from bone biopsies taken from newly diagnosed untreated CaP patients with (M1) or without (M0) bony metastasis. The stromal origin of these cells was confirmed by Western blot analysis using antibodies raised to stromal and epithelial markers. Media were conditioned over the cultures of these cells for 4 days, and levels of OPG were determined using an ELISA. The human prostate cancer cell line PC3 was challenged with TRAIL (50 ng/ml) in fresh media or in media supplemented with 50% conditioned media, and apoptosis was assessed using DAPI stain. The effects of specific removal of OPG activity by immunoprecipitation or by co-treatment of cultures with an alternative ligand for OPG (RANKL) were also tested. RESULTS AND
CONCLUSIONS: The presence of stromal cell conditioned media in PC3 culture significantly reduced TRAIL-induced apoptosis. All stromal cell lines isolated were shown to express OPG and to release this protein into the conditioned media. Immunoprecipitation of OPG and co-treatment of cultures with sRANKL reversed the protective effects of the conditioned media. These data suggest that at least part of the survival advantage gained by CaP cells in colonizing bone may be caused by the production of OPG by tumor-associated stromal cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355567     DOI: 10.1359/JBMR.040703

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

1.  TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

Authors:  Gaëlle Picarda; Valérie Trichet; Stéphane Téletchéa; Dominique Heymann; Françoise Rédini
Journal:  Am J Cancer Res       Date:  2011-10-09       Impact factor: 6.166

2.  Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.

Authors:  Irene Zinonos; Agatha Labrinidis; Michelle Lee; Vasilios Liapis; Shelley Hay; Vladimir Ponomarev; Peter Diamond; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

Review 3.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

4.  Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis.

Authors:  Steeve Kwan Tat; Nathalie Amiable; Jean-Pierre Pelletier; Christelle Boileau; Daniel Lajeunesse; Nicolas Duval; Johanne Martel-Pelletier
Journal:  Rheumatology (Oxford)       Date:  2009-09-17       Impact factor: 7.580

5.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis.

Authors:  Diptiman Chanda; Tatyana Isayeva; Sanjay Kumar; Jonathan A Hensel; Anandi Sawant; Girish Ramaswamy; Gene P Siegal; Matthew S Beatty; Selvarangan Ponnazhagan
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

6.  Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Jing-Ping Lin; Gang Zheng; Joel Moss
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

7.  Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.

Authors:  S S Cross; R F Harrison; S P Balasubramanian; J M Lippitt; C A Evans; M W R Reed; I Holen
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

Review 8.  Bone metastasis: the importance of the neighbourhood.

Authors:  Peter I Croucher; Michelle M McDonald; T John Martin
Journal:  Nat Rev Cancer       Date:  2016-05-25       Impact factor: 60.716

9.  Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis.

Authors:  Nicolás Anselmino; Michael Starbuck; Estefania Labanca; Javier Cotignola; Nora Navone; Geraldine Gueron; Ana C Zenclussen; Elba Vazquez
Journal:  Antioxid Redox Signal       Date:  2020-01-20       Impact factor: 8.401

10.  Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells.

Authors:  Annika Nordstrand; Jonas Nilsson; Ase Tieva; Pernilla Wikström; Ulf H Lerner; Anders Widmark
Journal:  Clin Exp Metastasis       Date:  2009-09-01       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.